Acute disseminated encephalomyelitis risk factors: Difference between revisions
Jump to navigation
Jump to search
| Line 19: | Line 19: | ||
===[[Genetic]] susceptibility=== | ===[[Genetic]] susceptibility=== | ||
* An association between [[ADEM]] and [[HLA-DR]] [[genes]] has been elucidated in a recent study. | * An association between [[ADEM]] and [[HLA-DR]] [[genes]] has been elucidated in a recent study<ref name="pmid22786832">{{cite journal| author=Imbesi D, Calabrò RS, Gervasi G, Casella C, Vita G, Musolino R| title=Does HLA Class II haplotype play a role in adult acute disseminated encephalomyelitis? Preliminary findings from a Southern Italy hospital-based study. | journal=Arch Ital Biol | year= 2012 | volume= 150 | issue= 1 | pages= 1-4 | pmid=22786832 | doi=10.4449/aib.v150i1.1384 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22786832 }} </ref>. | ||
* Patients with [[congenital]] [[adrenal]] [[hyperplasia]] or [[acquired]] [[adrenal]] [[insufficiency]] have been reported to suffer from | * Patients with [[congenital]] [[adrenal]] [[hyperplasia]] or [[acquired]] [[adrenal]] [[insufficiency]] have been reported to suffer from sequelae of [[encephalopathy]] with [[white matter]] [[lesions]]<ref name="pmid16540460">{{cite journal| author=Bergamaschi R, Livieri C, Uggetti C, Candeloro E, Egitto MG, Pichiecchio A | display-authors=etal| title=Brain white matter impairment in congenital adrenal hyperplasia. | journal=Arch Neurol | year= 2006 | volume= 63 | issue= 3 | pages= 413-6 | pmid=16540460 | doi=10.1001/archneur.63.3.413 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16540460 }} </ref>. | ||
==References== | ==References== | ||
Revision as of 06:33, 14 November 2022
|
Acute disseminated encephalomyelitis Microchapters |
|
Differentiating Acute disseminated encephalomyelitis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute disseminated encephalomyelitis risk factors On the Web |
|
American Roentgen Ray Society Images of Acute disseminated encephalomyelitis risk factors |
|
Acute disseminated encephalomyelitis risk factors in the news |
|
Directions to Hospitals Treating Acute disseminated encephalomyelitis |
|
Risk calculators and risk factors for Acute disseminated encephalomyelitis risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sujaya Chattopadhyay, M.D.[2]
Overview
Risk Factors
Infections
- The pathogens remain mostly unknown[1].
- The prodromal phase is characterised by flu-like symptoms (56-61%) and non-specific upper respiratory or gastrointestinal manifestations. The latent period varies from 4 to 41 days[2].
- Viral exanthems usually precede the onset of pediatric ADEM[3].
- The most common associated pathogens are viruses namely, Epstein-Barr, measles, mumps, rubella and coxsackie B[4]. Bacteria like Borrelia burgdorferi, Legionella and Mycoplasma are infrequently reported[5][6].
- ADEM shows a seasonal variation with increased incidence in winter and spring, probably due to the changes in the distribution of the implicated agents.
Vaccinations
- Immunisation is the precipitating factor for less than 5% of ADEM cases[7].
- The most frequent occurrences are with measles, mumps and rubella vaccines[8].
- The latent period varies from 2 to 30 days[8].
Genetic susceptibility
- An association between ADEM and HLA-DR genes has been elucidated in a recent study[9].
- Patients with congenital adrenal hyperplasia or acquired adrenal insufficiency have been reported to suffer from sequelae of encephalopathy with white matter lesions[10].
References
- ↑ Hung KL, Liao HT, Tsai ML (2001). "The spectrum of postinfectious encephalomyelitis". Brain Dev. 23 (1): 42–5. doi:10.1016/s0387-7604(00)00197-2. PMID 11226729.
- ↑ Berzero G, Cortese A, Ravaglia S, Marchioni E (2016). "Diagnosis and therapy of acute disseminated encephalomyelitis and its variants". Expert Rev Neurother. 16 (1): 83–101. doi:10.1586/14737175.2015.1126510. PMID 26620160.
- ↑ Berzero G, Cortese A, Ravaglia S, Marchioni E (2016). "Diagnosis and therapy of acute disseminated encephalomyelitis and its variants". Expert Rev Neurother. 16 (1): 83–101. doi:10.1586/14737175.2015.1126510. PMID 26620160.
- ↑ Berzero G, Cortese A, Ravaglia S, Marchioni E (2016). "Diagnosis and therapy of acute disseminated encephalomyelitis and its variants". Expert Rev Neurother. 16 (1): 83–101. doi:10.1586/14737175.2015.1126510. PMID 26620160.
- ↑ Menge T, Hemmer B, Nessler S, Wiendl H, Neuhaus O, Hartung HP; et al. (2005). "Acute disseminated encephalomyelitis: an update". Arch Neurol. 62 (11): 1673–80. doi:10.1001/archneur.62.11.1673. PMID 16286539.
- ↑ Esposito S, Di Pietro GM, Madini B, Mastrolia MV, Rigante D (2015). "A spectrum of inflammation and demyelination in acute disseminated encephalomyelitis (ADEM) of children". Autoimmun Rev. 14 (10): 923–9. doi:10.1016/j.autrev.2015.06.002. PMC 7105213 Check
|pmc=value (help). PMID 26079482. - ↑ Esposito S, Di Pietro GM, Madini B, Mastrolia MV, Rigante D (2015). "A spectrum of inflammation and demyelination in acute disseminated encephalomyelitis (ADEM) of children". Autoimmun Rev. 14 (10): 923–9. doi:10.1016/j.autrev.2015.06.002. PMC 7105213 Check
|pmc=value (help). PMID 26079482. - ↑ 8.0 8.1 Huynh W, Cordato DJ, Kehdi E, Masters LT, Dedousis C (2008). "Post-vaccination encephalomyelitis: literature review and illustrative case". J Clin Neurosci. 15 (12): 1315–22. doi:10.1016/j.jocn.2008.05.002. PMC 7125578 Check
|pmc=value (help). PMID 18976924. - ↑ Imbesi D, Calabrò RS, Gervasi G, Casella C, Vita G, Musolino R (2012). "Does HLA Class II haplotype play a role in adult acute disseminated encephalomyelitis? Preliminary findings from a Southern Italy hospital-based study". Arch Ital Biol. 150 (1): 1–4. doi:10.4449/aib.v150i1.1384. PMID 22786832.
- ↑ Bergamaschi R, Livieri C, Uggetti C, Candeloro E, Egitto MG, Pichiecchio A; et al. (2006). "Brain white matter impairment in congenital adrenal hyperplasia". Arch Neurol. 63 (3): 413–6. doi:10.1001/archneur.63.3.413. PMID 16540460.